ホーム › PubMed Lab 🤖 自分の AI で使う ⭐ 保存した論文

🔬 PubMed Lab

日本語で入力するだけで、PubMed の英語論文を検索できるリサーチアシスタントです。
卒論・研究テーマ探し、興味のある論文を効率よく見つけられます。

「免疫チェックポイント阻害薬と副腎不全の見逃されやすいサイン」の検索結果

24 件中 10 件を表示 (4350 ms) · ⭐ 保存した論文

AI が生成した英語クエリを見る
("immune checkpoint inhibitors"[MeSH] OR "checkpoint inhibitors" OR nivolumab OR pembrolizumab OR ipilimumab) AND ("adrenal insufficiency"[MeSH] OR "adrenal crisis" OR hypoadrenalism) AND ("early diagnosis"[MeSH] OR "delayed diagnosis"[MeSH] OR subtle OR atypical OR underdiagnosed OR overlooked)

💡 免疫チェックポイント阻害薬の主要薬剤名と副腎不全、診断遅延・見逃しに関連する用語を組み合わせました

🎓 卒論・修論テーマを AI が提案

この 5 本の論文を俯瞰して、あなたが実際に卒論・修論で研究できるテーマを 3 つ提案します。

残り 3 / 3 回 (今日)

📖 このサイトの解説記事から (日本語で読める)

PubMed Trivia が過去に取り上げた論文を日本語で解説している記事です。

🔍 PubMed の検索結果

  • The Rise of Oncoendocrinology: How Modern Cancer Therapies Are Reshaping Endocrine Practice.

    Nidha Shapoo, Noella Boma, Vladimir Gotlieb 他 · Medical sciences (Basel, Switzerland) · 2026

    The emergence of immune checkpoint inhibitors, targeted therapies, CAR T-cell therapy, and antibody-drug conjugates has transformed modern oncology, significantly improving survival across a wide range of malignancies. However, these advances have also introduced a growing spectrum of endocrine and metabolic complications, redefining the scope of endocrine practice. Therapy-induced endocrinopathie…

    📄 PubMed で読む (PMID: 42506316)
  • Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management.

    Pooja SirDeshpande, Soorya Bavikeri Shivakumara Hegde, Hassan Akhtar 他 · Cureus · 2025

    With an objective to review the clinical presentation, diagnosis, and management of immune checkpoint inhibitor (ICPi)-associated hypophysitis and pituitary dysfunction, we conducted a systematic review of 84 studies (2005-2025) involving 7,259 patients evaluated pituitary immune-related adverse events (irAEs) linked to CTLA-4 inhibitors, programmed cell death protein 1 (PD-1)/programmed cell deat…

    📄 PubMed で読む (PMID: 41510421)
  • Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: a systematic review and meta-ethnography of case reports.

    Ryuichi Ohta, Yoshinori Ryu, Kaoru Tanaka 他 · Frontiers in endocrinology · 2025

    Immune checkpoint inhibitors (ICIs) can cause adrenal insufficiency (AI) as an uncommon but potentially life-threatening immune-related adverse event (irAE). Early symptoms are often vague and may overlap with cancer-related fatigue or treatment side effects, contributing to diagnostic delays and under recognition. We conducted a systematic review and meta-ethnographic synthesis of 64 published ca…

    📄 PubMed で読む (PMID: 41103646)
  • Pembrolizumab-induced Thyroiditis, Hypophysitis and Adrenalitis: A Case of Triple Endocrine Dysfunction.

    Silvia Rossi, Francesca Silvetti, Monia Bordoni 他 · JCEM case reports · 2024

    Immune checkpoint inhibitor drugs can trigger autoimmune endocrine reactions as a known side effect. Several cases of immunotherapy-induced autoimmune endocrinopathies have been described, but multiple sequential endocrine toxicities are a rare occurrence. A 39-year-old patient with metastatic melanoma started adjuvant therapy with pembrolizumab. One month later he presented with asymptomatic thyr…

    📄 PubMed で読む (PMID: 39498471)
  • Isolated Adrenocorticotropic Hormone (ACTH) Deficiency as an Immune-Related Adverse Event Following Combination Immune Checkpoint Inhibitor Therapy.

    Mari Matsushiro, Kimitaka Shibue, Kazuki Osawa 他 · Cureus · 2024

    Isolated adrenocorticotropic hormone (ACTH) deficiency is a rare condition characterized by the sole impairment of ACTH secretion among the various hormones produced by the pituitary gland. This leads to secondary hypoadrenocorticism, manifesting symptoms such as fatigue, anorexia, weight loss, and altered consciousness. Recently isolated ACTH deficiency has emerged as an immune-related adverse ev…

    📄 PubMed で読む (PMID: 39040756)
  • Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors.

    Ruth Percik, Gadi Shlomai, Amir Tirosh 他 · Autoimmunity reviews · 2020

    Immune checkpoint inhibitors have introduced a new and heterogeneous class of immune-related adverse effects, with the endocrine system being a predominant target for autoimmunity. Autoimmune hypothalamic-pituitary-adrenal axis (HPA) diseases induced by checkpoint inhibitors are being increasingly recognized. We aimed to characterize the spectrum of checkpoint associated hypothalamic-pituitary-adr…

    📄 PubMed で読む (PMID: 31838158)
  • Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review.

    Sabrina Chiloiro, Simone Antonio De Sanctis, Bianca Parente 他 · Reviews in endocrine & metabolic disorders · 2026

    Immunotherapy-induced primary adrenal insufficiency (Ir-PAI) is a rare complication of immune checkpoint inhibitors (ICI). The clinical presentation is typically heterogeneous, with complex clinical pictures that may overlap with those of other endocrinopathies. Therefore, Ir-PAI may represent a life-threatening condition, with a possible subtle or acute onset, a high risk of electrolyte disorders…

    📄 PubMed で読む (PMID: 42215784)
  • Immune Checkpoint Inhibitor-Induced Thyroidal, Pancreatic, and Pituitary Dysfunction: Diagnostic Challenges in a Cancer Patient.

    Sara Gil Dos Santos, Raquel Calheiros, Joana Oliveira 他 · Acta medica portuguesa · 2026

    Immune checkpoint inhibitors (ICPIs)-induced endocrine immune-related adverse events (irAEs) are common, can appear concurrently, and can be overlooked due to their nonspecific presentation overlapping with cancer-related symptoms. We describe the case of a 47-year-old woman with metastatic colorectal cancer treated with combined ICPI therapy. She presented thyrotoxicosis right after starting ther…

    📄 PubMed で読む (PMID: 41312989)
  • A Triple Threat: Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis, Myocarditis, and Adrenal Insufficiency in a Patient With Metastatic Melanoma.

    Aamir Mohamed Nur, Mohammed Aamir · Cureus · 2025

    Immune checkpoint inhibitors (ICIs), such as ipilimumab and nivolumab, have revolutionized cancer therapy, particularly in advanced melanoma. By enhancing T-cell-mediated anti-tumor activity, these agents have significantly improved survival in metastatic disease. However, this immune activation can result in a range of immune-related adverse events (irAEs), which may affect virtually any organ sy…

    📄 PubMed で読む (PMID: 41246725)
  • Pembrolizumab-Induced Hypophysitis in the Setting of Renal Cell Carcinoma.

    Kassandra Ogbodu, Mukul Sharda, Naisarg B Vanani 他 · Cureus · 2025

    Immune checkpoint inhibitors (ICIs) like pembrolizumab have revolutionized oncology but are associated with immune-related adverse events, including rare cases of hypophysitis. Pembrolizumab-induced hypophysitis typically presents as an isolated adrenocorticotropic hormone (ACTH) deficiency. However, atypical cases with panhypopituitarism and pituitary enlargement have been reported. Here, we desc…

    📄 PubMed で読む (PMID: 40416222)